Literature DB >> 15698864

Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro.

Jun-Nian Zheng1, Ya-Feng Sun, Dong-Sheng Pei, Jun-Jie Liu, Xiao-Qing Sun, Jia-Chun Chen, Wei-Qi Cai, Wang Li, Jing-Yi Cao.   

Abstract

We treated in vitro human renal carcinoma cells (cell line 786-0) with the lipid-delivered peptide nucleic acids (PNAs) against Ki-67 gene. Corresponding control groups were treated with the antisense oligonucleotides (ASOs) of the same nucleobase sequence, and with mismatched PNAs. In cells treated by anti-Ki-67 PNAs, the Ki-67 expression rate, Ki-67 protein level, cell growth and the DNA synthesis-indicative 3H-thymidine incorporation rate were lower than in the ASO-treated groups, and reduced significantly compared to untreated controls, whereas the rate of apoptosis was markedly increased by PNA treatment. We conclude that anti-Ki-67 PNA has more strong (than ASO) and dose-dependent effects on the proliferation and apoptosis of human renal carcinoma cells. Our results indicate that the strategy of using PNA against the Ki-67 gene might be a promising approach in renal carcinoma therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698864     DOI: 10.1016/j.lfs.2004.10.034

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell.

Authors:  Junjie Liu; Lin Fang; Qian Cheng; Liantao Li; Changqing Su; Baofu Zhang; Dongsheng Pei; Jie Yang; Wang Li; Junnian Zheng
Journal:  Cancer Sci       Date:  2012-08-10       Impact factor: 6.716

2.  The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells.

Authors:  Xue-Qin Li; Dong-Sheng Pei; Guo-Wei Qian; Xiao-Xing Yin; Qian Cheng; Lian-Tao Li; Hui-Zhong Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2011-05-20

Review 3.  Ki67 targeted strategies for cancer therapy.

Authors:  C Yang; J Zhang; M Ding; K Xu; L Li; L Mao; J Zheng
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.